Clinical Trial Update: MRD Response-adapted Allo-HSCT for Adverse-risk AML [NA]

View source ↗

Summary

MRD response-adapted allogeneic stem cell transplantation for adverse-risk acute myeloid leukemia is currently recruiting at Peking University People's Hospital…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Snippet

Sponsor: Peking University People's Hospital | Conditions: Acute Myeloid Leukemia | NA | Status: RECRUITING